Description
A partial agonist of PPARγ (EC50 = 1.351 µM in a transactivation assay); decreases non-fasting plasma glucose levels in diabetic db/db mice (ED90 = 3 mg/kg per day); decreases plasma levels of insulin and glucose in an oral glucose tolerance test in diet-induced obese rats at 5 and 10 mg/kg per day; in doxorubicin-resistant K562 human myelogenous leukemia cells, it decreases P-gp levels, increases intracellular accumulation of rhodamine 123, and sensitizes cells to doxorubicin at 25 µM